{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T22:15:06Z","timestamp":1790720106342,"version":"4.1.0"},"reference-count":33,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,9,15]],"date-time":"2022-09-15T00:00:00Z","timestamp":1663200000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Neurol."],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>There is a growing body of mitochondrial disorders that are associated with headaches, albeit only one of them is currently listed in the latest International Classification of Headache Disorders, 3rd edition (ICHD-3). Headache frequency and headache presentation can vary widely in this respective patient group. Acute and preventive migraine treatment can be quite challenging\u2014the use of several established medications is often limited due to their side effects in the setting of mitochondrial dysfunction and multi-organ disease.<\/jats:p><\/jats:sec><jats:sec><jats:title>Case presentation<\/jats:title><jats:p>Along with a review of the literature on treatment options in patients with mitochondrial disorders and migraine headaches, we present the case of a 23-year-old male with a homozygous mutation in the mitochondrial single-strand binding protein (<jats:italic>SSBP1<\/jats:italic>) with chronic migraine with aura. After failing several standard of care prophylactics due to either side effects or inefficacy, he was successfully treated with a monoclonal anti-CGRP-antibody as a preventive migraine treatment. The monoclonal antibody was well tolerated and showed adequate efficacy with a sustained &amp;gt; 50% reduction in monthly headache days after 3 years of treatment.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Migraine is often challenging to treat in patients with mitochondriopathy due to therapy-limiting comorbidities. Monoclonal CGRP-antibodies might be a safe treatment option in the prevention of migraine headaches in patients with a mitochondrial disorder.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fneur.2022.958463","type":"journal-article","created":{"date-parts":[[2022,9,15]],"date-time":"2022-09-15T11:47:40Z","timestamp":1663242460000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":5,"title":["Case report: Monoclonal CGRP-antibody treatment in a migraine patient with a mutation in the mitochondrial single-strand binding protein (SSBP1)"],"prefix":"10.3389","volume":"13","author":[{"given":"Katharina","family":"Kaltseis","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisabetta","family":"Indelicato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregor","family":"Broessner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sylvia","family":"Boesch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,9,15]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"16080","DOI":"10.1038\/nrdp.2016.80","article-title":"Mitochondrial diseases","volume":"2","author":"Gorman","year":"2016","journal-title":"Nat Rev Dis Primers."},{"key":"B2","doi-asserted-by":"publisher","first-page":"961","DOI":"10.1007\/s00415-016-8086-3","article-title":"Expanded phenotypic spectrum of the m","volume":"263","author":"Altmann","year":"2016","journal-title":"J Neurol."},{"key":"B3","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1111\/head.13219","article-title":"Prevalence of headache in patients with mitochondrial disease: a cross-sectional study","volume":"58","author":"Kraya","year":"2018","journal-title":"Headache."},{"key":"B4","doi-asserted-by":"publisher","first-page":"1093","DOI":"10.1177\/0333102417723568","article-title":"Migraine in mitochondrial disorders: prevalence and characteristics","volume":"38","author":"Vollono","year":"2018","journal-title":"Cephalalgia."},{"key":"B5","doi-asserted-by":"publisher","first-page":"1151","DOI":"10.1007\/s13760-021-01630-4","article-title":"Headache and migraine in mitochondrial disease and its impact on life-results from a cross-sectional, questionnaire-based study","volume":"121","author":"Burow","year":"2021","journal-title":"Acta Neurol Belg."},{"key":"B6","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1016\/j.mito.2020.05.004","article-title":"Mitochondrial migraine; a prevalence, impact and treatment efficacy cohort study","volume":"53","author":"Tiehuis","year":"2020","journal-title":"Mitochondrion."},{"key":"B7","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1177\/0333102417738202","volume":"38","author":"3rd","year":"2018","journal-title":"Cephalalgia"},{"key":"B8","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1172\/JCI128514","article-title":"SSBP1 mutations cause mtDNA depletion underlying a complex optic atrophy disorder","volume":"130","author":"Del Dotto","year":"2020","journal-title":"J Clin Invest."},{"key":"B9","doi-asserted-by":"publisher","first-page":"596","DOI":"10.1046\/j.1468-2982.1997.1705596.x","article-title":"Prophylactic treatment of migraine with bisoprolol: a placebo-controlled study","volume":"17","author":"van de Ven","year":"1997","journal-title":"Cephalalgia."},{"key":"B10","first-page":"268","article-title":"Prevention of migraine using bisoprolol. Results of a double-blind study versus metoprolol","volume":"110","author":"W\u00f6rz","year":"1992","journal-title":"Fortschr Med."},{"key":"B11","doi-asserted-by":"publisher","first-page":"694","DOI":"10.1111\/head.14101","article-title":"Erenumab for migraine prevention in a patient with mitochondrial encephalopathy, lactate acidosis, and stroke-like episodes syndrome: a case report","volume":"61","author":"Naegel","year":"2021","journal-title":"Headache."},{"key":"B12","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1212\/01.wnl.0000078931.87815.b3","article-title":"Response to sumatriptan in headache of MELAS syndrome","volume":"61","author":"Iizuka","year":"2003","journal-title":"Neurology."},{"key":"B13","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1038\/gim.2017.107","article-title":"Patient care standards for primary mitochondrial disease: a consensus statement from the Mitochondrial Medicine Society","volume":"19","author":"Parikh","year":"2017","journal-title":"Genet Med."},{"key":"B14","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1038\/s41582-021-00509-5","article-title":"Diagnosis and management of migraine in ten steps","volume":"17","author":"Eigenbrodt","year":"2021","journal-title":"Nat Rev Neurol."},{"key":"B15","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1007\/s11940-019-0558-1","article-title":"Current status of antiepileptic drugs as preventive migraine therapy","volume":"21","author":"Parikh","year":"2019","journal-title":"Curr Treat Options Neurol."},{"key":"B16","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1007\/164_2016_2","article-title":"Toxicity of antiepileptic drugs to mitochondria","volume":"240","author":"Finsterer","year":"2017","journal-title":"Handb Exp Pharmacol."},{"key":"B17","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1186\/s10194-015-0516-6","article-title":"Improvement of migraine symptoms with a proprietary supplement containing riboflavin, magnesium and Q10: a randomized, placebo-controlled, double-blind, multicenter trial","volume":"16","author":"Gaul","year":"2015","journal-title":"J Headache Pain"},{"key":"B18","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1111\/j.1468-1331.2004.00813.x","article-title":"High-dose riboflavin treatment is efficacious in migraine prophylaxis: an open study in a tertiary care centre","volume":"11","author":"Boehnke","year":"2004","journal-title":"Eur J Neurol."},{"key":"B19","doi-asserted-by":"publisher","first-page":"e039358","DOI":"10.1136\/bmjopen-2020-039358","article-title":"Coenzyme Q10 supplementation for prophylaxis in adult patients with migraine-a meta-analysis","volume":"11","author":"Sazali","year":"2021","journal-title":"BMJ Open."},{"key":"B20","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1111\/jcpt.12548","article-title":"Prophylaxis of migraine headaches with riboflavin: a systematic review","volume":"42","author":"Thompson","year":"2017","journal-title":"J Clin Pharm Ther."},{"key":"B21","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ymgme.2017.09.009","article-title":"Therapies for mitochondrial diseases and current clinical trials","volume":"122","author":"El-Hattab","year":"2017","journal-title":"Mol Genet Metab."},{"key":"B22","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1016\/j.spen.2013.09.002","article-title":"Mitochondrial dysfunction in migraine","volume":"20","author":"Yorns","year":"2013","journal-title":"Semin Pediatr Neurol."},{"key":"B23","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1038\/s41582-019-0255-4","article-title":"The metabolic face of migraine - from pathophysiology to treatment","volume":"15","author":"Gross","year":"2019","journal-title":"Nat Rev Neurol."},{"key":"B24","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1177\/0333102412452048","article-title":"Magnetic resonance spectroscopy in migraine: what have we learned so far?","volume":"32","author":"Reyngoudt","year":"2012","journal-title":"Cephalalgia."},{"key":"B25","doi-asserted-by":"publisher","first-page":"5774","DOI":"10.12659\/msm.904549","article-title":"Extrinsic calcitonin gene-related peptide inhibits hyperoxia-induced alveolar epithelial type II cells apoptosis, oxidative stress, and reactive oxygen species (ROS) production by enhancing notch 1 and homocysteine-induced endoplasmic reticulum protein (HERP) expression","volume":"23","author":"Bai","year":"2017","journal-title":"Med Sci Monit."},{"key":"B26","doi-asserted-by":"publisher","first-page":"1561","DOI":"10.1177\/0333102420949202","article-title":"Migraine and aura triggered by normobaric hypoxia","volume":"40","author":"Frank","year":"2020","journal-title":"Cephalalgia."},{"key":"B27","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1111\/head.13081","article-title":"The trigeminovascular pathway: role of CGRP and CGRP receptors in migraine","volume":"57","author":"Edvinsson","year":"2017","journal-title":"Headache."},{"key":"B28","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1177\/0333102418821662","article-title":"CGRP ligand and receptor monoclonal antibodies for migraine prevention: evidence review and clinical implications","volume":"39","author":"Dodick","year":"2019","journal-title":"Cephalalgia."},{"key":"B29","doi-asserted-by":"publisher","first-page":"821","DOI":"10.3389\/fphys.2019.00821","article-title":"Protective role of \u03b1-Calcitonin gene-related peptide in cardiovascular diseases","volume":"10","author":"Kumar","year":"2019","journal-title":"Front Physiol."},{"key":"B30","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1186\/s10194-021-01360-1","article-title":"Cardiovascular outcomes in adults with migraine treated with eptinezumab for migraine prevention: pooled data from four randomized, double-blind, placebo-controlled studies","volume":"22","author":"Smith","year":"2021","journal-title":"J Headache Pain."},{"key":"B31","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1001\/jamaneurol.2021.4678","article-title":"Assessment of erenumab safety and efficacy in patients with migraine with and without aura: a secondary analysis of randomized clinical trials","volume":"79","author":"Ashina","year":"2022","journal-title":"JAMA Neurol."},{"key":"B32","doi-asserted-by":"publisher","first-page":"e497","DOI":"10.1212\/WNL.0000000000008743","article-title":"Vascular safety of erenumab for migraine prevention","volume":"94","author":"Kudrow","year":"2020","journal-title":"Neurology."},{"key":"B33","doi-asserted-by":"publisher","first-page":"764","DOI":"10.1136\/jnnp-2020-322850","article-title":"Diagnostic and therapeutic aspects of hemiplegic migraine","volume":"91","author":"Di Stefano","year":"2020","journal-title":"J Neurol Neurosurg Psychiatry."}],"container-title":["Frontiers in Neurology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fneur.2022.958463\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,20]],"date-time":"2022-09-20T14:38:43Z","timestamp":1663684723000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fneur.2022.958463\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9,15]]},"references-count":33,"alternative-id":["10.3389\/fneur.2022.958463"],"URL":"https:\/\/doi.org\/10.3389\/fneur.2022.958463","relation":{},"ISSN":["1664-2295"],"issn-type":[{"value":"1664-2295","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,9,15]]},"article-number":"958463"}}